ArticleMetabolomics : Official journal of the Metabolomic Society
Response of Degarelix treatment in human prostate cancer monitored by HR-MAS
Article in Metabolomics : Official journal of the Metabolomic Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Histone Lactylation-Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.Journal of translational medicine · 2023Article
- Role of asparagine biosynthesis pathway inFrontiers in microbiology · 2023Article
- The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.Metabolites · 2022Review
- Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- Pharmacometabolomics by NMR in Oncology: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.Metabolites · 2021Review
- Metabolism of prostate cancer by magnetic resonance spectroscopy (MRS).Biophysical reviews · 2020Review
- ApcScientific reports · 2020Article
- Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer.NMR in biomedicine · 2019Review
- Metabolomic prostate cancer fields in HRMAS MRS-profiled histologically benign tissue vary with cancer status and distance from cancer.NMR in biomedicine · 2019Article
- NMR Spectroscopy for Metabolomics Research.Metabolites · 2019Review
- NMR-based metabolomics studies of human prostate cancer tissue.Metabolomics : Official journal of the Metabolomic Society · 2018Review
- Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS.Scientific reports · 2018Article
- TranslatingJCO precision oncology · 2018Article
- Profiling Prostate Cancer Therapeutic Resistance.International journal of molecular sciences · 2018Review
- The crucial role of multiomic approach in cancer research and clinically relevant outcomes.The EPMA journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe androgen receptor (AR) is the master regulator of prostate cancer cell metabolism. Degarelix is a novel gonadotrophin-releasing hormone blocker, used to decrease serum androgen levels in order to treat advanced human prostate cancer. Little is known of the rapid metabolic response of the human prostate cancer tissue samples to the decreased androgen levels.
objectivesTo investigate the metabolic responses in benign and cancerous tissue samples from patients after treatment with Degarelix by using HRMAS
methodsUsing non-destructive HR-MAS
resultsLactate, alanine and t-choline concentrations were significantly elevated in high-grade prostate cancer samples when compared to benign samples in untreated patients. Decreased androgen levels resulted in significant decreases of lactate and t-choline concentrations in human prostate cancer biopsies.
conclusionsThe reduced concentrations of lactate and t-choline metabolites due to Degarelix could in principle be monitored by in vivo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.